| Samsara [IOT] - Last Close: $9.90 Samsara is running hot after a strong earnings report. The IoT company released its fiscal Q3 results in Thursday's after-hours, and the report exceeded expectations. Samsara reported an adjusted loss of -$(0.02) per share and easily beat the consensus estimate of a -$(0.06) per share loss. Revenues of $168.9 million also topped the consensus of $155.4 million. Samsara also hiked its full-year revenue guidance. IOT is one of today's top performers with a 22.3% gain. My Take: IOT is facing some resistance at $10, but this rally could help it break out of its trading range. RA Medical Systems [RMED] - Last Close: $3.17 RA Medical is riding the wave from yesterday's rally. The stock saw big gains yesterday after Catheter Precision announced its lead VIVO system has been used in more than 800 procedures in Europe and the US. The two companies have entered into a definitive merger agreement, and Cather will become a wholly-owned RMED subsidiary upon closing. As a result of the pending merger, RMED shares closed with a 29.3% gain on Thursday because of Catheter's upbeat press release. RMED is carrying the momentum into today's premarket. Shares are up 32.1% on active volume. My Take: RMED is a very tiny stock, so there could be some low-level market manipulation going on here. Hard to tell at this point, but I would be wary of this one. Don't get caught holding the bag. Anavex Life Sciences [AVXL] - Last Close: $8.87 Anavex's latest clinical update is sending shares soaring. The clinical-stage biopharma firm said its Anavex 2-73 drug combo met its primary and secondary endpoints in a Phase 2b/3 study in Alzheimer's patients. Treatment with Anavex 2-73 reduced clinical decline and was 167% more likely to improve function over placebo. The drug was generally safe and well tolerated, with dizziness being reported as the most common adverse effect. Anavex will meet with regulators to determine the next steps. Shares of AVXL are up 23.6%. My Take: Anavex could get a massive boost if it can get an effective Alzheimer's treatment to market. This data seems encouraging, but the drug still has to pass Phase 3 to make it to market, and it could take quite some time to get there. Rigel Pharmaceuticals [RIGL] - Last Close: $0.6841 Shares of Rigel Pharma are rallying on a key drug approval. On Thursday evening, the biotech company announced that the US FDA approved REZLIDHIA for the treatment of adults with acute myeloid leukemia. The approval came after a Phase 2 study showed a 35% complete remission rate, with a media duration of response of 25.9 months. "We are delighted by the approval of REZLIDHIA based on the strength of data supporting the efficacy and safety of the product," said Rigel CEO Raul Rodriguez. The company will now push to launch and commercialize the drug in the US, and it intends to work with partners to bring the drug to international markets. RIGL is today's most active premarket stock, and it's up 30.1%. My Take: RIGL definitely needed some good news. Shares have been in decline since August, and it recently received a deficiency letter from Nasdaq. However, this catalyst could prove to be a pivot point for the stock. GainersWinc [WBEV] >> +29.1%Revelation Biosciences [REVBU] >> +24.9%Helbiz [HLBZ] >> +18.9%DeclinersElanco Animal Health [ELAN] >> (18.9%)Zscaler [ZS] >> (9.5%)Asana [ASAN] >> (14.8%)' Cracker Barrel Old Country Store, Inc. [CBRL] ... AM
Genesco Inc. [GCO] ... AM
Ehang Holdings Limited [EH] ... AM
Kirkland'S, Inc. [KIRK] ... AM
Jianpu Technology Inc [JT] ... AM | 